Definitive therapy depends on the cause: *Symptomatic treatment can be given by blood transfusion, if there is marked anemia. A positive Coombs test is a relative contraindication to transfuse the patient. In cold<unk>  there is advantage in transfusing warmed blood. *In severe immune-related<unk> , steroid therapy is sometimes necessary. *In steroid resistant cases, consideration can be given to rituximab or addition of an immunosuppressant (azathioprine, cyclophosphamide). *Association of methylprednisolone and intravenous immunoglobulin can control hemolysis in acute severe cases. *Sometimes splenectomy can be helpful where extravascular hemolysis, or hereditary spherocytosis, is predominant (i.e., most of the red blood cells are being removed by the spleen). Mitapivat was approved for medical use in the United States in February 2022.
Hemolytic anemia
Transfusion-dependent anemia
Acquired hemolytic anemia
Myelophthisic anemia
Sideroblastic anemia
Basophilia
Mixed autoimmune hemolytic anemia
Megaloblastic anemia